Improved NYVAC-Based Vaccine Vectors

Karen V. Kibler1,*, Carmen E. Gomez2,*, Beatriz Perdiguero2, Shukmei Wong1, Trung Huynh1, Susan Holechek1, William Arndt1, Victoria Jimenez2, Ruben Gonzalez-Sanz2, Karen Denzler1, Elias K. Haddad3, Ralf Wagner5, Rafick P. Sékaly3,4, James Tartaglia6, Giuseppe Pantaleo7, Bertram L. Jacobs1,*, Mariano Esteban2

1 The Biodesign Institute at Arizona State University, Tempe, Arizona, United States of America, 2 Centro Nacional de Biotecnologia-Consejo Superior de Investigaciones Científicas, Madrid, Spain, 3 Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, Florida, United States of America, 4 University of Montreal, Montreal, Canada, 5 University of Regensburg, Regensburg, Germany, 6 Sanofi-Pasteur, Swiftwater, Pennsylvania, United States of America, 7 Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Abstract

While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) have been encouraging and suggest that further improvements of the prime/boost vaccine combination of a poxvirus and protein are needed. With this aim, in this investigation we have generated derivatives of the candidate vaccinia virus vaccine vector NYVAC with potentially improved functions. This has been achieved by the re-incorporation into the virus genome of two host range genes, KIL and C7L, in conjunction with the removal of the immunomodulatory viral molecule B19, an antagonist of type I interferon action. These novel virus vectors, referred to as NYVAC-C-KC and NYVAC-C-KC-ΔB19R, have acquired relevant biological characteristics, giving higher levels of antigen expression in infected cells, replication-competency in human keratinocytes and dermal fibroblasts, activation of selective host cell signal transduction pathways, and limited virus spread in tissues. Importantly, these replication-competent viruses have been demonstrated to maintain a highly attenuated phenotype.

Introduction

Following the eradication of smallpox through the use of an efficient live vaccinia virus (VACV) for vaccination, and thereafter, the discovery of poxviruses as recombinant vectors expressing a large range of foreign genes [1,2], pox viruses became natural candidates for vectors to vaccinate against multiple disease-causing organisms. However, the rate of complications from wtVACV led researchers and regulators to seek pox virus vectors that would be highly attenuated to provide greater safety in humans. Three of the most well-characterized highly attenuated pox vectors have been ALVAC [3,4], MVA [5], and NYVAC [3]. ALVAC, which is a vaccine strain of canary pox virus, is naturally attenuated in a human host, and does not replicate productively in human cells. MVA, which is also a virus that does not replicate in human cells, was passaged in chick embryo fibroblasts (CEF) to achieve attenuation. MVA suffered several large deletions and numerous point mutations during passage in CEFs that are responsible for its attenuation. NYVAC was deleted of 18 specific open reading frames that are present in the parental Copenhagen strain, including the host range genes KIL and C7L. NYVAC is replication-incompetent in most human cells. While one of the advantages of replication-deficient viruses is their safety profiles, it has been postulated that efficacy of these viruses is limited by the failure to replicate and the attendant limitation in antigen accumulation during virus infection.

Among the many heterologous antigens that have been expressed in these replication-defective poxvirus vaccine vectors are those derived from HIV [4,6]. Most recently, ALVAC was included in the RV144 phase III HIV vaccine clinical trial conducted in Thailand in which a 31% efficacy rate against HIV infection was achieved after three years [7]. With the trial’s encouraging demonstration that a vaccine regimen can protect to at least a limited extent, one conclusion of these findings is that the components of vaccination need to be optimized to afford protection to a large percentage of vaccinees. With this aim, in this report we describe the generation of improved NYVAC recombinants expressing the HIV antigens Env/Gag-Pol-Nef (E/GPN) from clade C. These improvements have been obtained by removal of a viral gene that inhibits type I interferon (IFN) pathways and by restoration of replication competence in human cells by inserting the KIL and C7L host range genes back into the viral genome. Our findings demonstrate that these new constructs (NYVAC-C-KC and NYVAC-C-KC-ΔB19R) have acquired new
biological properties distinct from the parental NYVAC-C, which make them potentially improved vaccine vector candidates for human application.

Materials and Methods

Ethics Statement

All animal work at Arizona State University has been conducted in compliance with national and international guidelines. This study was approved by the Institutional Animal Care and Use Committee at Arizona State University, Tempe, Arizona, under Protocol #10-0970R.

All animal work at CNB-CSIS has been conducted in compliance with national and international guidelines and with the Royal Decree (RD 1201/2005). These studies were approved by the Ethical Committee of Animal Experimentation of Centro Nacional de Biotecnología, Madrid, Spain, under Permit numbers 152/07 and 080030.

PBMCs for signal transduction assays were obtained from healthy blood donors recruited by the Blood Transfusion Center of Madrid; donations were approved by the ethics commission of the Center and written informed consent was obtained from the donors; all information was kept confidential by the Blood Center.

Construction of recombinant viruses

Generation of NYVAC-C-AB19R. The plasmid transfer vector pGem-RG-B19R was used for the construction of the recombinant virus NYVAC-C-AB19R, with the B19R ORF deleted, was obtained by sequential cloning of five DNA fragments containing dsRed2 and rsGFP genes and B19R recombination flanking sequences into the plasmid pGem-7Zf- (-Promega). The dsRed2 gene under the control of the synthetic early/late promoter was amplified by PCR from plasmid pGem-RsRed2 with oligonucleotides Red2-B (5'-GAATTCGAGAAAGTTAAGAAGATAC-3') (Bam HI site underlined), digested with Bam HI and Eco RI and inserted into the Cla I/Bam HI-digested pGem-7Zf- to generate pGem-Red-GFP. The purified grown stock of virus was referred to as P3. The B10R locus of NYVAC-C-AB19R was deleted in a similar manner.

Generation of NYVAC-C-KC and NYVAC-C-KC-AB19R. The C7L and K1L genes were amplified from the Copenhagen genome using the following primers: NY1, 5'-GGCATCGGTTGGTTTTAATCATGATG 3'; NY2, 5'-GTCCTTACCTATCGATGCGGTTGGTTTTATCATAGTGAATTT-3' (Cla I site underlined) and pGem-Red-GFP was previously digested with Xba I and Eco RI and inserted into pGem-Red-GFP using Lipofectamine (Invitrogen) according to the manufacturer’s protocol (Lipofectamine, Invitrogen), in 35 mm dishes; cells were infected with the parental virus, either NYVAC or NYVAC-C, at a multiplicity of infection (MOI) of 0.05 by adding the virus to the transfection mix. After 30 minutes of incubation, 1 ml of OptiMEM with 1% serum was added to each dish. Cells were scraped into the medium at 36 hours post-infection. Following three rounds of freeze/thaw, the IVR scrape was used to infect Vero cells (kind gift of Sanofi Pasteur) to select for viruses competent for large plaque formation in Vero cells. The same method was used to insert KC into NYVAC-C-AB19R.

PCR analysis

To test for deletion of B19R, viral DNA was extracted by the method of SDS-Protease K-phenol from BSC-40 cells mock-infected or infected at an MOI of 5 with wtNYVAC, NYVAC-C or NYVAC-C-AB19R. Primers LFB19R-BamHI-F and LFB19R-BamHI-R spanning the B19R flanking regions were used for PCR analysis of B19R locus. The amplification reactions were carried out with Platinum Taq DNA polymerase (Invitrogen, San Diego, CA). For verification of the KC fragment, primers NY1 and NY4
were used on viral DNA obtained by standard phenol extraction from BHK-infected cells (ATCC).

Expression of HIV-1 proteins gp120 and GPN

To verify the correct expression of the HIV-1 proteins gp120 and GPN from the viruses, monolayers of either BSC-40 or BHK cells were mock-infected or infected at an MOI of 5 with wtNYVAC, NYVAC-C, NYVAC-C-KC, NYVAC-C-AB19R, or NYVAC-C-KC-AB19R. At 48 hours post-infection, cells were lysed in Laemmli buffer, cell extracts fractionated by 10% SDS-PAGE and analyzed by Western blot using rabbit polyclonal anti-gp120 antibody (Centro Nacional de Biotecnologia; diluted 1:3000) or polyclonal anti-gag p24 serum (ARP 429, NIBSC, Centralised Facility for AIDS reagent, UK; diluted 1:1000) followed by anti-rabbit-HRP (Sigma; diluted 1:5000) to evaluate the expression of gp120 and GPN proteins respectively.

Analysis of virus growth

To determine virus-growth profiles, monolayers of CEF cells grown in 12-well tissue culture plates were infected in duplicate at an MOI of 0.01 with wtNYVAC, NYVAC-C or NYVAC-C-AB19R. Following virus adsorption for 60 minutes at 37 °C, the inoculum was removed. The infected cells were washed once with DMEM without serum and incubated with fresh DMEM containing 2% FCS at 37 °C in a 5% CO2 atmosphere. At different times post-infection (0, 24, 48 and 72 hours), cells were removed by scraping (lysates at 5×10^7 cells/ml), freeze-thawed three times and briefly sonicated. Virus titers in cell lysates were determined by crystal violet staining in BSC-40 cells.

To compare replication competence in human cells, NYVAC-C, NYVAC-C-KC, and NYVAC-C-KC-AB19R were used to infect HeLa cells (ATCC) at an MOI of 5. At 0, 6, 12, and 24 hours post-infection cells were scraped into the medium, pelleted, and the supernatant discarded. The cell pellets were resuspended in 200 μl medium and titers were obtained in BHK cells. Multi-step growth curves were done at an MOI of 0.01 in the indicated cell lines, keratinocytes (Invitrogen) and dermal fibroblasts (Lonza). IFN treatment was 1000 units/ml added for 24 hours prior to infection.

Signal Transduction Assays

HeLa cells and human keratinocytes were infected at an MOI of 5 and allowed to incubate for 6 hours. Cell lysates were prepared by standard methods and analyzed by Western blots probed with antibodies specific to the phosphorylated forms of PKR (Cell Signaling), eIF2α (Cell Signaling), and IRF3 (Epitomic), or to the internal control, GAPDH (Abcam).

For human peripheral blood mononuclear cells (PBMCs), phospho-protein levels present in extracts of cells infected with different recombinant viruses were measured simultaneously by Cytometric Bead Array (CBA) using an LSR II flow cytometer (Becton Dickinson). In CBA technology, different bead populations with distinct fluorescence intensities had been coated with capturing antibodies specific for different analytes. These bead populations could be resolved in the fluorescence channels of the flow cytometer. After the beads had been incubated with 50 μl of sample, different analytes in the sample were captured by their corresponding beads. The protein captured beads were then mixed with phycoerythrin-conjugated detection antibodies to form sandwich complexes. Following incubation, washing and acquisition of fluorescence data, the results were generated in graphical format using the BD CBA software. The concentrations of total and phospho STAT1 were measured simultaneously using the Cell Signaling Master Buffer Kit (BD Biosciences Pharmingen, CA, USA; Cat. No. 558223). For this CBA analysis, 4×10^5 PBMCs were mock-infected or infected at an MOI of 5 with wtNYVAC, NYVAC-C, NYVAC-C-KC, NYVAC-C-AB19R or NYVAC-C-KC-AB19R. At 4 hours post-infection, cells were centrifuged at room temperature for 10 minutes at 2000 rpm and

Transcriptional analysis

Ex vivo derived plasmacytoid dendritic cells (pDC, [8]) and myeloid dendritic cells (mDC, [8]) were infected with 0.1 MOI of NYVAC-C, NYVAC-C-KC, NYVAC-C-AB8RAV19R and NYVAC-C-KC-AB8RAV19R for 6 hours. Cells were then harvested for RNA extraction and gene array analysis. Gene array analysis was performed on BeadChips using the Illumina platform.

RNA extraction, amplification, hybridization, and scanning were performed as described previously [9]. Briefly, total RNA was purified from sorted dendritic cells using RNA extraction kits (Qiagen). RNA was quantified and assessed for quality using a spectrophotometer (NanoDrop Technologies). Total RNA was then amplified by incorporating biotin using the Illumina Total Prep RNA Amplification kit, which is based on the Eberwine amplification protocol. The biotinylated cRNA was hybridized onto Illumina Human RefSeq-B V3 BeadChips (PMBC samples, [8]) at 58 C for 20 hours and quantified using an Illumina BeadStation 500GX scanner and Illumina BeadScan software.

Gene array analysis: scanned raw data was screened and inspected for quality. Genes with intensities below background in all samples were removed and then minimum-replaced (a surrogate-replacement policy) using the mean background value of the built-in Illumina probe controls. Normalization of chips was done by quantile-normalization.

Gene expression data was analyzed using the R software package. Genes are filtered by detection call and by variance filters to allow a reduction in the number of tests and a corresponding increase in power of the differential gene expression analysis [10]. The resulting matrix was log2 transformed and used as input for the resulting comparison was set to 0.05 in this analysis. Determination of commonly and uniquely regulated genes is based solely on the nominal p values and fold change.

All data is MIAME compliant and the raw data has been deposited in a MIAME compliant database.

Measurement of apoptotic cell death by cell cycle analysis

The different stages of cell cycle and the percentage of cells with subG0 DNA content were analyzed by propidium iodide (PI) staining. Briefly, HeLa cells were mock-infected or infected at an MOI of 5 with NYVAC-C, NYVAC-C-KC, NYVAC-C-AB19R or NYVAC-C-KC-AB19R. At 24 hours post-infection, cells were centrifuged at room temperature for 10 minutes at 2000 rpm and
supernatants discarded. Pellets were resuspended in detergent lysis buffer and cells stained with PI. After an incubation of 30 minutes at 37 °C in the dark, the percentage of cells with hypodiploid DNA content was determined using an LSR II flow cytometer (Becton Dickinson). The results are expressed as fold increase in apoptotic cells with respect to uninfected cells.

Pathogenicity in newborn mice

For studies in newborn mice, pregnant CD1 mice were purchased from Charles River at 10 days gestation. The animals were housed one animal per cage. Intracranial infections with the indicated viruses, using a total volume of 10 µL, were conducted at 48 to 72 hours post-birth of the pups (at least 10 pups per virus), using a 27-gauge needle, as previously described [11]. Animals were monitored twice daily for 14 days for morbidity and mortality.

Mice immunization for biodistribution

BALB/c mice were purchased from Harlan. To analyze the biodistribution of virus recombinants in animals, BALB/c were immunized by intraperitoneal route (IP) with a dose of \(2 \times 10^7\) PFU/mouse of WR(TK\(^{-}\)), NYVAC-C, NYVAC-C-KC, NYVAC-C-ΔB19R or NYVAC-C-KC-ΔB19R. At different times post-infection (24, 48 and 72 hours) mice were sacrificed and mouse tissues were processed for plaque assay titration. Peritoneal cells were harvested by mouse peritoneal cavity lavage with 10 ml of sterile PBS, centrifuged at room temperature for 5 minutes at 1200 rpm and stored at −70 °C. Spleens, draining lymph nodes,
ovaries, and livers were dissected under sterile conditions and stored at −70°C. Peritoneal cells were resuspended in 200 μl complete DMEM media and tissues from individual mice were homogenized in 200 μl complete DMEM media using an Eppendorf-fitted Dounce homogenizer. The production of infectious virus in different mouse tissues was tested by plaque assay in BSC-40 cells. The virus titer was expressed as Plaque Forming Units (PFU) per gram of protein. Protein content in tissue extracts was measured with a bicinchoninic protein assay reagent kit (Pierce Co., Rockford, IL).

Another test was also used for biodistribution by measuring levels of antigen expression in mice infected with recombinants NYVAC and NYVAC-KC expressing the luciferase marker. The recombinant viruses WR-luc and NYVAC-luc have been previously described [12,13]. The recombinant NYVAC-KC-luc was generated by the re-insertion of KC into the genome of previously described [12,13]. The recombinant NYVAC-KC-luc expressing the luciferase marker. The levels of antigen expression in mice infected with recombinants were measured by Western blot (Fig. 1C).

Results

Generation of NYVAC-C-ΔB19R with a deletion of the virus inhibitor of type I IFN

To originally construct the parental NYVAC virus, VACV-Cop had been deleted of eighteen open reading frames (ORFs), including the TK gene [14]. For the potential use of NYVAC as an HIV vaccine vector, the genes encoding the HIV clade C antigens envelope (env), gag, polymerase (pol), and nef, were inserted into the empty TK locus to create NYVAC-C [15]. The immune response elicited by NYVAC-C was tested in mice [15,16], monkeys [17] and humans [18,19]. The results indicated that the vector was immunogenic, but that some improvements were needed, as the response triggered in the three different models was not strong and was largely directed against env. Moreover, priming with a DNA vector expressing the homologous HIV antigens was needed, as fewer than 40% of the human volunteers responded to two doses of the vaccine alone [18].

To improve the vector, we compiled a list of vaccinia virus genes that are present in the NYVAC genome that are known to interrupt or abrogate host immune system pathways, particularly those of the interferon system [20]. We selected for deletion in the NYVAC genome the gene B19R (B18R in WR strain), which encodes a soluble type I IFN binding protein [21], and B8R, which encodes a soluble type II IFN binding protein [22]. NYVAC-C-ΔB19R was constructed by replacing the B19R gene with a GFP/dsRed selection cassette through the use of in vivo recombination (IVR). The viral genome then resolves to remove the duplicate coding regions, leaving an empty locus in the place of the targeted gene. The process to insert the cassette and remove it is illustrated in Figure 1A. The B8R, B19R double deletion was prepared in a similar manner, starting with NYVAC-C-ΔB19R. Characterization of NYVAC-C-ΔB19R is shown in Figures 1 B–D. Similar data has been obtained for the double mutant (data not shown). Deletion of B19R was verified by PCR (Fig. 1B) and expression of the HIV antigens was verified by Western blot (Fig. 1C). The deletion mutant NYVAC-C-ΔB19R replicated in CEFs, as shown in Figure 1D, to titers similar to those of the parental NYVAC-C.

Generation of replication-competent NYVAC Vectors

Because NYVAC has limited replication capacity in cultured human cells [14], our next goal was to produce a modified NYVAC vector able to complete the replication cycle in cultured human cells, but still maintaining an attenuated phenotype. K1L and C7L are two of the genes that were deleted during the construction of NYVAC, and these are both host range genes [23]. To restore replication in human cells, we inserted the K1L and C7L genes back into the NYVAC genome. Figure 2 shows a schematic diagram of the genome sequences assembled by PCR and inserted into the genome through IVR to create NYVAC-C-KC, NYVAC-C-KC-ΔB19R and NYVAC-C-KC-ΔB8RΔB19R.

Replication in human cells

To verify that the presence of the two genes, K1L and C7L, in the modified virus does result in improved ability of the virus to replicate in human cells leading to higher levels of antigen expression, we examined first the replication capacity of NYVAC-C-KC compared to that of NYVAC-C, in a single step growth curve in HeLa cells (Fig. 3A). NYVAC-C-KC and NYVAC-C-KC-ΔB19R replicated under these experimental conditions in HeLa cells, but NYVAC-C did not. To be certain that the addition of the K1L and C7L genes would restore replication in human cell types that are physiologically relevant to poxvirus infection, we analyzed multi-step growth curves in human keratinocytes and human dermal fibroblasts and compared the NYVAC-C-KC replication in these primary cells (Fig. 3B and 3C) to that observed in HeLa cells (Fig. 3A). Though NYVAC-C did not replicate in any of the tested cells, NYVAC-C-KC and NYVAC-C-KC-ΔB19R replicated to titers comparable to that of wtVACV-Cop in human keratinocytes and dermal fibroblasts (Fig. 3B and 3C). While wtVACV-Cop was fully resistant to treatment with IFN, NYVAC-C-KC and NYVAC-C-KC-ΔB19R showed increased sensitivity to IFN, especially in dermal fibroblasts. Thus, the addition of the K1L and C7L genes to NYVAC did restore replication competence in human cells.

Transgene expression

Insertion of K1L and C7L into NYVAC-C and deletion of B19R also had a dramatic effect on transgene expression. The K1L and C7L genes have been shown to decrease activation of PKR and inhibit the subsequent phosphorylation and inactivation of eIF2α [24,25,26]. This can be seen in Figure 4B. NYVAC-C infection induced an intermediate amount of PKR phosphorylation compared to infection with wtVACV-Cop (VC-2) on the one hand and virus deleted for the PKR inhibitor, E3L (vP1080), on the other hand. Insertion of K1L and C7L into NYVAC-C inhibited activation of PKR to background levels seen in VC2-infected cells. Inhibition of PKR activation in NYVAC-C-KC-infected cells was accompanied by an increase of expression of gag-pol-nef protein and gp120 in infected human cells, compared to cells infected with NYVAC-C (Fig. 4A). Deletion of B19R from NYVAC-C increased phosphorylation of PKR and eIF2α, nearly...
Figure 4. Signal transduction. A) Cells were infected at an MOI of 5; lysates were prepared at 6 hours post-infection and proteins were identified by a standard Western blot probed with anti-gp120 or anti-gag. B) HeLa cells were infected with the indicated viruses and harvested at 6 hours post-infection. Lysates were prepared and analyzed by Western blot to detect phosphorylation of shown signal transduction pathway components. C) Human keratinocytes were infected with the indicated viruses and harvested 6 hours post-infection. Lysates were prepared and analyzed by Western blot to detect phosphorylation of shown signal transduction pathway components. D) Comparative analysis of P-STAT1 protein levels of
to the levels of virus deleted for E3L. This increase in both activation of PKR and phosphorylation of eIF2α was accompanied by a dramatic decrease in transgene expression. Insertion of K1L and C7L into NYVAC-C-AB19R reversed this trend, leading to a restoration of transgene protein synthesis to the level seen in cells infected with NYVAC-C-KC.

**Induction of Host Responses**

Since B19 blocks the effects of type I IFN, we wanted to determine if deletion of B19R would have an effect on signaling downstream of IFN binding to its receptor on cells. The STAT-1 pathway, which is downstream of IFN induction, was not activated by infection with any virus deleted B19R (wtNYVAC, NYVAC-C or NYVAC-C-KC, Fig. 4D). In fact, infection with any of these viruses led to decreased STAT-1 phosphorylation compared to mock-infected cells. However, deletion of B19R led to phosphorylation of STAT-1, even in the virus with K1L and C7L restored, compared to infection with the viruses containing B19R.

Several components of the virus sensing system are inducible by IFN (e.g., RIG-I and MDA-5). Since deletion of B19R can lead to IFN-induced signaling, we wanted to determine if these viruses affected phosphorylation of IRF-3. IRF-3 is a key transcription factor, which when phosphorylated and activated can lead to induction of type I IFN, and IFN is an important mediator between the innate and adaptive immune systems. Figure 4B shows the results of Western blot analysis of lysates from HeLa cells infected with either VC2 (wtNYVAC), NYVAC-C-KC, NYVAC-C-AB19R, or NYVAC-C-KC-AB19R to detect phosphorylation of IRF-3. wtNYVAC-Cop did not lead to phosphorylation of IRF-3, consistent with previously published results [27]. vP1080 (Copenhagen deleted of the E3L gene) was a strong activator of IRF-3 phosphorylation because the E3L protein is not present to mask the dsRNA [27]. Neither NYVAC-C nor NYVAC-C-KC induced detectable phosphorylation of IRF-3. However, deletion of B19R from either of these viruses resulted in phosphorylation of IRF-3. Results in human keratinocytes (Fig. 4C) were similar to those in HeLa cells, although we did observe donor-to-donor variation in the activation patterns (data not shown).

The signal transduction results were extended by microarray analysis of infected cells, as shown in Figure 4E. The detailed microarray data from human dendritic cells (DCs) infected with the NYVAC vectors has been recently described [8]. Shown here is representative data from DCs infected with either NYVAC-C or NYVAC-C-KC, or either of those viruses deleted also of both B8R and B19R. The results from infection with this double-deletion mutant were indistinguishable from those of the single deletion of B19R only (data not shown). Infection with either NYVAC-C or NYVAC-C-KC induced very little change to any of the shown IFN-inducible genes, consistent with the IRF-3 phosphorylation and STAT-phosphorylation results shown in Figure 4B and 4D. The deletion of B8R and B19R from NYVAC-C results in a strong inflammatory response, as evidenced by the transcriptional up-regulation of all the genes shown on the graph, again consistent with the results seen in Figure 4B and 4D. With the insertion of K1L and C7L, this response was tempered; infection with NYVAC-C-KC-AB8RAB19R induced increased transcriptional levels of seven of the genes shown, relative to NYVAC-C-KC [IFI35, IFI44, IFI44L, IFT1, IFT3, IFTTM1, and IFTMT2]. The lower level of induction of these genes by NYVAC-C-KC-AB8RAB19R compared to that of NYVAC-C-ΔB8RAB19R is consistent with signal transduction data, since NYVAC-C-KC-AB8RAB19R induced less IRF-3 and STAT-1 phosphorylation than did NYVAC-C-AB8RAB19R (data not shown).

Since activation of PKR has previously been shown to lead to induction of apoptosis, we assayed for the ability of these modified viruses to induce apoptosis. Consistent with the activation of PKR in HeLa cells (Fig. 4B), apoptosis in HeLa cells infected with non-replication vs. replication competent B19R deletion mutants. Phospho-STAT1 levels present in extracts of cells infected with different recombinant viruses were measured by Cytometric Bead Array (CBA) using an LSR II flow cytometer. The concentrations of total and phospho STAT1 were measured simultaneously using the Cell Signaling Master Buffer Kit (BD Biosciences Pharmingen). For this CBA analysis, PBMCs were mock-infected or infected at an MOI of 5 with NYVAC wt, NYVAC-C, NYVAC-C-KC, NYVAC-C-AB19R or NYVAC-C-KC-AB19R. At 4 hours post-infection, cells were harvested and processed for CBA analysis as described in Materials and Methods and according to manufacturer’s recommendations. Results are given as the ratio between phospho and total STAT1.

Data from a subset of the IFN-induced genes is shown. Fold increase (decrease) is normalized to results for mock-infected cells.

doi:10.1371/journal.pone.0025674.g004
NYVAC-C or NYVAC-C-ΔB19R was increased when normalized to uninfected cells, while the level of apoptosis was not increased in cells infected with the viruses containing the K1L and C7L genes (Fig. 5).

Safety profile

Though our goal was to improve the parental NYVAC vaccine vector, it was equally important to maintain sufficient safety levels with the pox vector. To compare the pathogenicity of NYVAC-C-KC constructs to existing vaccines, we utilized a newborn mouse model, the most sensitive mouse model available for detecting pox virus pathogenesis [11]. Newborn mice were inoculated intracranially (IC) with the indicated viruses. As can be seen in Figure 6, wtVACV-Cop was highly pathogenic in this model, with an LD_{50} of only 10 pfu. VACV-CopC, with the loss of the TK gene, is further attenuated by about one log, and has an LD_{50} comparable to that of the New York City Board of Health (NYCBH) [28] strain of VACV, the strain of VACV currently used for vaccination against smallpox. NYVAC-C-KC was attenuated by approximately four logs compared to NYCBH. Deletion of B19R from NYVAC-C-KC further attenuated the virus by approximately one log, approaching the attenuation of MVA and NYVAC-C. Thus, the safety profile of NYVAC-C-KC-ΔB19R, despite this construct being nearly fully replication-competent in primary human skin cells in culture, is in the same general range as the highly attenuated, replication-restricted vaccinia virus strains, MVA and NYVAC-C.

Since most of the complications due to use of vaccinia virus require spread from the site of inoculation, we followed two approaches to characterize spread of the virus in infected animals: one determining virus titers in different organs and the second, evaluating viral expression by the levels of the marker luciferase in NYVAC recombinants.

To measure titers in different organs, mice were inoculated intraperitoneally (IP) with 2×10^7 pfu/mouse of virus and at different days post infection the animals were sacrificed and the presence of virus in the peritoneal wash, ovaries, liver, spleen, and lymph nodes was measured. As shown in Figure 7, the WR strain of VACV was detectable at high titers in all tissue samples (peritoneum, ovaries, liver spleen and lymph nodes), even up to 72 hours post-infection. Infectious NYVAC-C or NYVAC-C-ΔB19R was not detectable in any tissue at any time. Both NYVAC-C-KC and NYVAC-C-KC-ΔB19R were transiently detectable in the peritoneum and ovaries, but resolved by 48 hours post-infection. Levels of NYVAC-C-KC were similar to wtVACV-WR in the peritoneal cavity, but 4- to 5-fold lower than wtVACV-WR in ovaries. NYVAC-C-KC-ΔB19R was detectable in 5-fold and 100-fold lower amounts in the peritoneal cavity and ovaries, respectively, compared to wtVACV-WR.

These results were confirmed with recombinant viruses expressing luciferase. Groups of mice were infected IP with 2×10^7 pfu/mouse of WR-luc, NYVAC-luc or NYVAC-KC-luc and at different time points, levels of luciferase were evaluated in mouse tissues. As shown in Figure 8, luciferase expression remained elevated in animals infected with the fully replication-competent WR-luc, while the levels were reduced in NYVAC-infected animals. Luciferase expression was intermediate for animals infected with NYVAC-KC-luc.

Discussion

An important consideration in the HIV/AIDS vaccine field is the nature of the vectors needed for protective efficacy. While...
numerous different combinations of vectors are being considered as vaccine regimens, one combination has been shown to be partially effective. This has been shown in the phase III Thai clinical study (RV144) with the vaccine combination of a canarypox virus (ALVAC) and the monomeric protein gp120, giving 31% protection against HIV infection [7]. The modest efficacy of the RV144 trial suggests that improvement of the vaccination protocol is possible. Since ALVAC is a replication-restricted virus in human cells and the other candidate VACV vectors, MVA and NYVAC, are also replication-restricted, it is possible that improvements of these vectors might be achieved through enhancement of their replication capacity. In this investigation we have achieved this goal by the re-insertion of the host restriction genes K1L and C7L into the NYVAC genome. Re-insertion of these two genes restored replication capacity in human cultured cells, including physiologically relevant primary keratinocytes and primary dermal fibroblasts. A concern of replication-competence in human cultured cells has been tempered by the demonstration that the replication-competent viruses described in this manuscript are highly attenuated compared to other replication-competent strains. This has been demonstrated through intracranial inoculation of the vectors in newborn mice. Clearly the vector NYVAC-C-KC is highly attenuated compared to the Copenhagen and NYCBH strains (Fig. 6). The attenuation was further improved by deleting the type I IFN inhibitor B19. The likely reason that increased attenuation is associated with deletion of B19R is that type I IFN induced during virus infection is no longer blocked by the virus inhibitor B19 and, hence, pro-inflammatory pathways are more readily activated (Fig. 4).

The consequences of the incorporation of the host genes K1L-C7L into NYVAC-C include the enhanced expression of foreign antigens, such as the HIV-1 protein gp120 and the fusion protein gag-pol-nef in cultured cells (Fig. 4A). Viral protein expression in vaccinia virus-infected cells is often regulated by activation of the cellular protein, PKR, which when activated, effectively inhibits translation of viral proteins. Poxviruses use several mechanisms to...
block activation of PKR, including the dsRNA binding protein E3L [27,29]. However, work done by others has shown that K1L is also necessary to prevent activation of PKR in vaccinia virus-infected cells [24,30], and that even expression of early viral proteins is down-regulated in the absence of K1L. Therefore, antigen expression by the viral vector is enhanced by the presence of K1L. We also detected increased luciferase expression in animals infected with NYVAC-KC-luc. In this case, the increased level of antigen expression may result from a combination of restored replication-competence which likely leads to an increase in the number of cells infected in the animal, and to a de novo increase in translation in infected cells in the animal. In the absence of a mechanism to separate replication-competence from increased protein expression in the individual cell, it is difficult to ascertain the contribution of each.

It is curious that deletion of B19R has such a dramatic effect on activation of PKR and phosphorylation of IRF-3. Our hypothesis is that B19 normally blocks the priming effect resulting from small amounts of IFN secreted from the infected host cell. In the absence of B19, this priming effect is allowed to take place, inducing pathogen-associated molecular pattern (PAMP) sensors, such as RIG-I and PKR, and initiating signal transduction pathways that may enhance the adaptive immune response against the antigen. The highly-attenuated phenotype of the NYVAC-C-KC-ΔB19R virus, along with higher antigen expression levels than observed with its parental virus NYVAC-C, and its ability to induce pro-inflammatory signaling and pro-inflammatory gene expression, suggest that this virus provides a potential improved vaccine vector for human application.

Previous studies on the immunological characteristics of NYVAC-C have been documented in different models: mouse [15,16], macaque [17] and human clinical trials [18,19]. The results obtained thus far indicate that NYVAC-C is immunogenic but needs further improvements. In fact, prime/boost combination with DNA vectors is needed to expand the breadth and strength of the immune responses to HIV antigens. In the phase I clinical studies, two doses of NYVAC-C given intramuscularly resulted in positive responses to HIV antigens in fewer than 40%
vaccines [18,19]. It was only after priming with DNA vectors that responses rose to about 90% of vaccinees [10]. It is likely that the limited expression of HIV antigens and the replication-restriction responses rose to about 90% of vaccinees [18]. It is likely that the vaccinees [18,19]. It was only after priming with DNA vectors that in vitro CD8 T cells vectors showing activation of pathways involved in antigen processing and presentation, enhanced cross-presentation to HIV-specific CD8 T cells, and proliferation of specific memory CD8 T cells in vitro [8].

Acknowledgments
The authors wish to thank Constance Chamberlain and Nobuko Fukushima for technical assistance.

Author Contributions
Conceived and designed the experiments: RW RS JT GP BJ ME EH KK. Performed the experiments: KK CG BP SW TH SH WA VJ RG KD EH. Analyzed the data: KK EH RS BJ ME CG. Contributed reagents/materials/analysis tools: RW JT RS BJ ME. Wrote the paper: KK CG BJ ME.

References
1. Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93: 11441–11446.
2. Paoletti E (1996) Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 93: 11349–11353.
3. Paoletti E, Tartaglia J, Taylor J (1994) Safe and effective poxvirus vectors–NYVAC and ALVAC. Dev Biol Stand 82: 63–69.
4. Franchini G, Gurunathan S, Baglios I, Pletkin S, Tartaglia J (2004) Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3: 87–98.
5. Drexler I, Staib C, Sutter G (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15: 506–512.
6. Gomez CE, Najera JL, Krupa M, Esteban M (2008) The poxvirus vectors MVA and NYVAC as antigen delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97–120.
7. Rerks-Ngarm S, Pratittithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220.
8. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, et al. (2011) Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 6: e16819.
9. Yellows fever vaccine induces integrated multilineage and polymorphic immune responses. J Exp Med 205: 3119–3131.
10. Hackstadt AJ, Hess AM (2009) Filtering for increased power for microarray data analysis. BMC Bioinformatics 10: 11.
11. Li Z, Rubin SA, Taffs RE, Merchlinsky M, Ye Z, et al. (2004) Mouse neurotoxicity test for vaccinia-based smallpox vaccines. Vaccine 22: 1496–1493.
12. Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callicero I, Gonzalez-Asegueda G, et al. (2007) Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 88: 2473–2478.
13. Rodriguez JF, Rodriguez D, Rodriguez JR, McGowan EB, Esteban M (1998) Expression of the firefly lucerase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc Natl Acad Sci U S A 95: 16476–16471.
14. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, et al. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 190: 217–232.
15. Gomez CE, Najera JL, Jimenez V, Bider K, Will J, et al. (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25: 1969–1992.
16. Wild J, Bider K, Kostler J, Frachette MJ, Jeffs S, et al. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22: 309–319.
17. Mooij P, Balia-Jaghoorosinh SS, Beenhakker N, van Haalten P, Baak I, et al. (2009) Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. J Virol 83: 5001–5009.
18. Harari A, Bart PA, Sohr W, Tapia G, Garcia M, et al. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63–77.
19. Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, et al. (2008) EVO1: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26: 3153–3161.
20. Perdiguero B, Esteban M (2009) The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29: 501–508.
21. Colamoneci OR, Domanski P, Swirzer SM, Larner A, Buller RM (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270: 15974–15978.
22. Alcami A, Smith GL (1995) Vaccinia, cosxop, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69: 4633–4639.
23. Perkus ME, Geoebl SJ, Davis SW, Johnson GP, Limbach K, et al. (1990) Vaccinia virus host range genes. Virology 179: 276–286.
24. Meng X, Jiang C, Arsenio J, Dick K, Gao J, et al. (2009) Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol 83: 10627–10636.
25. Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM, Esteban M (2006) Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80: 6033–6047.
26. Willis KL, Patel S, Xiang Y, Shinder JL (2009) The effect of the vaccinia K1 protein on the PKR-eIF2alpha pathway in RK13 and HeLa cells. Virology 394: 73–81.
27. Langland JO, Kash JC, Carter V, Thomas MJ, Katz MG, et al. (2006) Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. J Virol 80: 10083–10095.
28. Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, et al. (2003) Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9: 1125–1130.
29. Jacobs BL, Langland JO (1996) When two strands are better than one: the EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26: 3153–3161.
30. Shinder JL, Jin XL (2004) The vaccinia K1L gene product inhibits host NF-kappaB activation by preventing Bap31alpha degradation. J Virol 78: 3553–3560.